AI summary · may contain errors
Neoadjuvant camrelizumab plus apatinib in resectable stage II–IVA HNSCC achieved an overall major pathological response rate of 29.3% (12/41) with low grade ≥3 toxicity (2.4%).
Moving in Clinical Cancer Research, JNCI: Journal of the National Cancer Institute, JAMA Oncology, Journal of Clinical Oncology, Oncogene, Annals of Oncology, Frontiers in Genetics and bioRxiv.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Neoadjuvant camrelizumab plus apatinib in resectable stage II–IVA HNSCC achieved an overall major pathological response rate of 29.3% (12/41) with low grade ≥3 toxicity (2.4%).
AI summary · may contain errors
Perioperative camrelizumab plus chemotherapy improved 2-year event-free survival to 77.8% versus 46.1% in resectable stage III–IVB head and neck squamous cell carcinoma.
AI summary · may contain errors
Early oral nutritional supplementation at CCRT start in stage II–IVA nasopharyngeal carcinoma patients reduced >5% weight loss by completion (65.4% vs 80.7%; RR 0.81).
AI summary · may contain errors
WCDD115 radiosensitizes NRF2-competent head and neck squamous cell carcinoma by suppressing one-carbon metabolism and nucleotide biosynthesis, enhancing radiation-induced DNA damage.
AI summary · may contain errors
For non-metastatic stage IB–III nasopharyngeal carcinoma, the updated CSCO-ASCO guideline strengthens definitive treatment with IMRT plus image guidance and MRI-based target delineation as core components.
AI summary · may contain errors
Platinum-based chemotherapy combined with a PD-1 inhibitor is recommended as preferred first-line systemic therapy for medically fit patients with recurrent and/or metastatic nasopharyngeal carcinoma.
AI summary · may contain errors
In a multicenter cohort of 6,049 nonmetastatic nasopharyngeal carcinoma patients treated with IMRT, TNM-9 improved prognostic performance over TNM-8 but left T- and N-category discrimination limited.
AI summary · may contain errors
ESCCseeker, a peripheral blood mononuclear cell DNA methylation risk tool for esophageal squamous cell carcinoma in China, achieves AUCs up to 0.987 and enables triage.
AI summary · may contain errors
In the NEO-CESQ phase II trial of perioperative cemiplimab for stage III–IV resectable cutaneous squamous cell carcinoma, major pathological response occurred in 11 of 25 patients (44%).
AI summary · may contain errors
A quantitative immunofluorescence assay measured HER3, EGFR, and TROP2 protein across 329 HNSCC patients, with 100%, 97.5%, and 98.4% of cases above assay LOD.
AI summary · may contain errors
SomaGauss-SV detects high-frequency somatic structural variations in laryngeal squamous cell carcinoma, including a simple repeat expansion present in 28/39 (71.79%) patients.
AI summary · may contain errors
EphA4 shapes head and neck squamous cell carcinoma outcomes by cell-type–specific negative regulation of AKT, with EphA4 loss increasing AKT activation and altering Treg, macrophage, CD8, and cancer-cell behaviors.
AI summary · may contain errors
CD266+ myofibroblasts in unresectable/recurrent/metastatic head and neck squamous cell carcinoma are linked to resistance to immunochemotherapy via PIEZO1-driven ECM stiffening and immune exclusion.
AI summary · may contain errors
Neoadjuvant bintrafusp alfa in 6 head and neck squamous cell carcinoma patients rapidly reduces activated LRRC15+ cancer-associated fibroblasts and stromal collagen within 3 weeks.
AI summary · may contain errors
The manuscript was withdrawn and is not intended to be cited, because the authors are revising and extending the work’s scope.
AI summary · may contain errors
Neoadjuvant nivolumab plus carboplatin and paclitaxel in stage III–IV HPV-negative SCCHN and stage II–III HPV-positive oropharyngeal SCCHN achieved a 45% primary-site pCR.
AI summary · may contain errors
HPV-DeepSeek, a whole-genome HPV liquid biopsy, detects HPV+ cancers with 99% sensitivity and specificity and classifies viral physical state from plasma at diagnosis.
AI summary · may contain errors
Neoadjuvant nivolumab plus carboplatin and paclitaxel in locally advanced, resectable head and neck squamous cell carcinoma improves pathologic response rates versus chemotherapy or immunotherapy alone.
AI summary · may contain errors
Danvatirsen plus pembrolizumab did not improve overall response rate versus pembrolizumab alone in first-line recurrent/metastatic head and neck squamous cell carcinoma with PD-L1 CPS ≥1.
AI summary · may contain errors
Transarterial radioembolization monotherapy is the only hepatocellular carcinoma (HCC) macrovascular invasion option with consistently low heterogeneity, yielding pooled 1-year overall survival of 34% (95% CI 20%–48%).
AI summary · may contain errors
Weekly cisplatin 40 mg/m² with 70-Gy concurrent radiation is noninferior to cisplatin 100 mg/m² every 3 weeks for 2-year locoregional control in non-nasopharyngeal locally advanced head and neck squamous cell carcinoma.
AI summary · may contain errors
In previously untreated advanced esophageal squamous cell carcinoma with tumor cell PD-L1 ≥1%, nivolumab plus chemotherapy or nivolumab plus ipilimumab improved overall survival at 5 years (HR 0.62 for both).
Journals this month
Topics moving, week to 17 Nov 2026
By field